| O L S H A N |
1325 AVENUE OF THE AMERICAS ● NEW YORK, NEW YORK 10019
TELEPHONE: 212.451.2300 ● FACSIMILE: 212.451.2222 |
EMAIL: AFINERMAN@OLSHANLAW.COM
DIRECT DIAL: 212.451.2289
| January 15, 2021 |
VIA EMAIL AND EDGAR
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
| Attention: | Jason L. Drory Division of Corporation Finance Office of Life Sciences |
| Re: | Summit Therapeutics Inc. Registration Statement on Form S-3 Filed January 8, 2021 File No. 333-251958 |
Ladies and Gentlemen:
On behalf of Summit Therapeutics Inc. (“Summit”), we enclose Summit’s request for acceleration of the above-referenced Registration Statement to 4:15 p.m., Eastern time, on Tuesday, January 19, 2021, or as soon as possible thereafter.
Please advise the undersigned of the effectiveness of the Registration Statement.
| Very truly yours, | |
|
/s/ Adam W. Finerman | |
| Adam W. Finerman |
| cc: | Robert Duggan Michael Donaldson |
| O L S H A N F R O M E W O L O S K Y L L P | WWW.OLSHANLAW.COM |
SUMMIT THERAPEUTICS INC.
One Broadway, 14th Floor
Cambridge, MA 02142
| January 15, 2021 |
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
| Attention: | Jason L. Drory Division of Corporation Finance Office of Life Sciences |
| Re: | Summit Therapeutics Inc. Registration Statement on Form S-3 Filed January 8, 2021 File No. 333-251958 |
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, Summit Therapeutics Inc. hereby requests that the effectiveness of the above-referenced Registration Statement be accelerated so that it will become effective at 4:15 p.m., Eastern time, on Tuesday, January 19, 2021, or as soon as possible thereafter.
| Very truly yours, | ||
| SUMMIT THERAPEUTICS INC. | ||
| By: |
/s/ Michael Donaldson | |
| Michael Donaldson | ||
| Chief Financial Officer | ||